Redeye comments on GiG Software’s announcement of a directed share issue which strengthens the compa...
Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citize...
Redeye is positive about Optomed´s launch of its next-gen camera, Optomed Lumo.
Today, we hosted a presentation by Incap's CEO Otto Pukk, at our virtual Nordic EMS seminar on Thurs...
Redeye comments on this morning’s news that Kancera has received positive feedback on the planned cl...
Redeye concludes that Systemair is able to show firm margins despite a muted topline in their fourth...
Redeye provides a brief comment on today’s news regarding Scibase's first order in Italy.
Redeye embraces the directed share issue of cSEK158m and expects the cash position to suffice until ...
Redeye comments on Faron’s ASCO 2025 presentation of full phase II BEXMAB data in high-risk MDS.
Redeye comments on Enviro’s press release from last Friday, stating that Infiniteria (the joint vent...
Analysguiden ser potentialen i Studentbostäder i Norden och målet om en belåningsgrad om max 60% til...
Redeye views the agreement with Eli Lilly, close second in the obesity space after Novo Nordisk, as ...
Directed share issue and new financial targets Sales SEK 400m by '28e and EBIT/cash flow positive b...
Redeye returns with a more in-depth take on the Q4 results.
Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates a...
Redeye initiates coverage of Litium, a Nordic mid-market-focused SaaS platform for digital commerce.
Analysguiden inleder bevakning av Case Group AB som haft en stark tillväxt under 2024–2025 med ökat ...
CEO Arni Ekholm has decided to retire on March 2026.
Redeye comments on Jumpgate’s announcement regarding the approval of SEK13.
CEO Andgren's network could help DTC efforts Breaking into hospitality market could be complex Capac...
